An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of ANORO administered in Korean subjects with chronic obstructive pulmonary disease (COPD) in usual practice (204511) First published 26/10/2015 Last updated 26/03/2024 EU PAS number:EUPAS11397 Study Finalised